---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-003682"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2026-05-11T21:10:17+00:00"
generated_at: "2026-05-11T21:13:33.308464+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract

## Summary
- NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.
- NeuRX admits it lacked legal right to sublicense without Davion's written consent; Davion would have declined approval.
- Cancellation follows notice that NeuRX breached representations and warranties in the definitive agreement.
- Davion demands Odyssey withdraw public statements that it holds a BreastCheck sublicense.

## SEC filing metadata
- accession: 0001683168-26-003682
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2026-05-11T21:10:17+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316826003682/0001683168-26-003682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316826003682/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-003682
- JSON: https://secwatch.observer/filing/0001683168-26-003682.json
- Plain text: https://secwatch.observer/filing/0001683168-26-003682.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.